CTRI/2012/01/002390Other3 期
A Phase 3 Clinical Study to Determine the Pharmacokinetics, Safety and Efficacy of rVWF:rFVIII and rVWF in the Treatment of Bleeding Episodes in Subjects Diagnosed with Von Willebrand Disease
试验速览
- 阶段
- 3 期
- 状态
- Other
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •The subject has been diagnosed with:
- •o type 3 VWD (VWF:Ag <=3 IU/dl) or
- •o severe non-type 3 VWD (VWF:RCo <20 IU/dL) or
- •o type 2N VWD (FVIII:C <10% and historically documented genetics)
- •The subject, who participates for the treatment for bleeding episodes, has had a minimum of 6 documented bleeds (medical history) requiring VWF coagulation factor replacement therapy during the previous3 years prior to enrollment.
- •The subject has a Karnofsky score >=60.
- •If female of childbearing potential, subject presents with a negative pregnancy test
- •The subject agrees to employ adequate birth control measures for the duration of the study.
- •Subject is willing and able to comply with the requirements of the protocol.
排除标准
- •The subject has been diagnosed with pseudo VWD or another hereditary or acquired coagulation disorder other than VWD (eg qualitative and quantitative platelet disorders or elevated PT/international normalized ratio [INR] >1.4).
- •The subject has a documented history of a VWF:RCo half-life of <6 hours.
- •The subject has a history or presence of a VWF inhibitor at screening.
- •The subject has a history or presence of a factor VIII (FVIII) inhibitor with a titer >=0.4 BU (by Nijmegen assay) or >=0.6 BU (by Bethesda assay).
- •The subject has a known hypersensitivity to any of the components of the study drugs, such as to mouse or hamster proteins.
- •The subject has a medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis, mild asthma, food allergies or animal allergies.
- •The subject has a medical history of a thromboembolic event.
- •The subject is HIV positive with an absolute CD4 count <200/mm3.
- •The subject has been diagnosed with cardiovascular disease (New York Heart Association [NYHA] classes 1-4)
- •The subject has an acute illness (eg, influenza, flu-like syndrome, allergic rhinitis/conjunctivitis, non-seasonal asthma) at screening.
- •The subject has been diagnosed with significant liver disease as evidenced by any of the following: serum alanine aminotransferase (ALT) 5 times the upper limit of normal; hypoalbuminemia; portal vein hypertension (eg, presence of otherwise unexplained splenomegaly, history of esophageal varices).
- •The subject has been diagnosed with renal disease, with a serum creatinine level >=2 mg/dL.
- •In the judgment of the investigator, the subject has another clinically significant concomitant disease (eg, uncontrolled hypertension) that may pose additional risks for the subject.
- •The subject has been treated with an imunomodulatory drug, excluding topical treatment (eg, ointments, nasal sprays), within 30 days prior to signing the informed consent.
- •Subject is pregnant or lactating at the time of enrollment.
- •Subject has participated in another clinical study involving an IP or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational product or investigational device during the course of this study.
- •The subject has a history of drug or alcohol abuse within the 2 years prior to enrollment.
- •The subject has a progressive fatal disease and/or life expectancy of less than 3 months.
- •The subject is identified by the investigator as being unable or unwilling to cooperate with study procedures.
- •The subject suffers from a mental condition rendering him/her unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude.
- •The subject is in prison or compulsory detention by regulatory and/or juridical order
研究者
相似试验
招募中
3 期
A Phase 3 clinical study to determine the pharmacokinetics, safety and efficacy of rVWF:rFVIII and rVWF in the treatment of bleeding episodes in subjects diagnosed with von Willebrand diseaseCoagulation disorderHereditary deficiency of Von Willebrand Factor in blood1006447710005330NL-OMON38008Baxter4
进行中（未招募）
不适用
Clinical study to explore the pharmacokinetics, safety and efficacy of recombinant VWF (in combination with recombinant FVIII and recombinant VWF alone) in the treatment of bleeding episodes in patients with von Willebrand Disease.EUCTR2010-024108-84-ITBAXTER INNOVATIONS GMBH40
进行中（未招募）
不适用
Clinical study to explore the influence of the human body on the study drug, on the safety and the efficacy of recombinant VWF (in combination with recombinant FVIII and recombinant VWF alone) in the treatment of bleeding episodes in patients with von Willebrand Disease.EUCTR2010-024108-84-ATBaxter Innovations GmbH49
进行中（未招募）
不适用
Clinical study to explore the influence of the human body on the study drug, on the safety and efficacy of recombinant VWF (in combination with recombinant FVIII and recombinant VWF alone) in the treatment of bleeding episodes in patients with von Willebrand Disease.EUCTR2010-024108-84-DEBaxter Innovations GmbH49
进行中（未招募）
不适用
Clinical study to explore the influence of the human body on the studydrug, on the safety and the efficacy of recombinant VWF (in combinationwith recombinant FVIII and recombinant VWF alone) in the treatment ofbleeding episodes in patients with von Willebrand Disease.EUCTR2010-024108-84-SEBaxter Innovations GmbH49